Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 84

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 84
---
,983 12,373 39 %129,551 91,938 37,613 41 %Total research and development expenses$90,464 $61,905 $28,559 46 %$247,005 $173,590 $73,415 42 %

The increase in the majority of the categories above for the three and nine months ended September 30, 2025 since the corresponding prior period is as a result of the advancement of our clinical programs and the advancement of our preclinical portfolio.

The following table summarizes our research and development expenses by program for the three and nine months ended September 30, 2025 and 2024 (in thousands):

Three months ended September 30,$Change%ChangeNine months ended September 30,$Change%Change2025202420252024Paltusotine$18,823 $13,689 $5,134 38 %$50,552 $39,710 $10,842 27 %Atumelnant15,072 6,430 8,642 134 %33,982 15,595 18,387 118 %Early research and development programs9,264 6,598 2,666 40 %25,928 18,497 7,431 40 %Personnel expenses26,062 17,617 8,445 48 %76,827 50,489 26,338 52 %Stock-based compensation13,003 10,556 2,447 23 %37,921 29,612 8,309 28 %Other8,240 7,015 1,225 17 %21,795 19,687 2,108 11 %Total research and development expenses$90,464 $61,905 $28,559 46 %$247,005 $173,590 $73,415 42 %

The increase in research and development programs for the three and nine months ended September 30, 2025 as compared to the prior year periods was primarily due to clinical, manufacturing, and outside services costs associated with paltusotine for the treatment of carcinoid syndrome and atumelnant, preclinical, clinical, manufacturing, and outside services costs for early research and development programs, and increase in headcount and other increases to support the overall increased activities in